Hemostemix Inc. (CVE:HEM – Get Free Report)’s stock price fell 19.4% during mid-day trading on Thursday . The stock traded as low as C$0.14 and last traded at C$0.15. 519,694 shares changed hands during mid-day trading, a decline of 1% from the average session volume of 526,987 shares. The stock had previously closed at C$0.18.
Hemostemix Stock Down 19.4 %
The business has a 50 day simple moving average of C$0.20 and a 200-day simple moving average of C$0.12. The company has a debt-to-equity ratio of -55.07, a quick ratio of 0.48 and a current ratio of 0.04. The firm has a market capitalization of C$21.13 million, a price-to-earnings ratio of -4.23 and a beta of 0.20.
Hemostemix Company Profile
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
See Also
- Five stocks we like better than Hemostemix
- What Are Dividend Achievers? An Introduction
- Fastenal : Growth Trends, Challenges & Key Investment Insights
- What Are the FAANG Stocks and Are They Good Investments?
- 2 Auto Stocks to Let Go and 1 Worth Buying for the Long Haul
- Transportation Stocks Investing
- Biogen Stock Is Mutating Into a Value Play
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
